-
Innovation Ranking
Innovation Ranking – WuXi AppTec Co Ltd
WuXi AppTec Co Ltd (Wuxi AppTec) is a pharmaceutical and medical device outsourcing company. The company is mainly engaged in the discovery, development and production of small molecule drugs, cell therapies and gene therapies, as well as providing testing services for medical devices. Its services includes pharmaceutical drug discovery; laboratory, bio analytical, clinical, toxicology, regulatory, small molecule pharmaceutical development; consulting and training services; testing services for bio therapeutics and medical devices; research and development services for advanced therapies; chemistry services...
-
Company Insights
Innovation and Patenting activity of WuXi AppTec Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of WuXi AppTec Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Sector Analysis
Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition
M and A In Pharmaceutical Contract Manufacturing Industry Report Overview During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates. The Mergers and Acquisitions (M&A) in the Contract...
-
Company Profile
WuXi AppTec Co Ltd – Company Profile
WuXi AppTec Co Ltd (Wuxi AppTec) is a pharmaceutical and healthcare outsourcing company. It carries out research, discovery, and development of healthcare products. It provides biology services, small molecule contract research and development (CRDMO), medical device testing, clinical research, oligonucleotide, and peptide CRDMO, and cell and gene therapy services. Wuxi AppTec’s CRDMO services consists new drug development, material requirements, commercialization, and covers synthetic molecular modalities. The company operates in Asia, Europe, and North America. Wuxi AppTec is headquartered in Shanghai,...
Add to Basket -
Sector Analysis
China Contract Manufacturing Market Outlook – Trends, Ambitions, Key Players, Investment and Value Chain
There is an increasing reliance on contract manufacturing and development services due to the growing regulatory complexity surrounding drug production and development. China has been focusing on establishing volume and enhancing capabilities for innovative high-value drug production. This will enable the Chinese pharma manufacturers to compete with US and European equivalents in terms of obtaining contracts for lucrative treatments such as gene and cell therapies. China is also upgrading its manufacturing capabilities, boosting innovation, and strengthening its position in a...
-
Thematic Analysis
Drug Manufacturing Sector Scorecard – Thematic Intelligence
Pharma supply chains are complex processes through which drugs are developed, manufactured, and delivered to patients. Additionally, outsourced manufacturing is a key supply chain component which is primarily driven by increased drug consumption and the development of more advanced treatments. Therefore, pharma companies are under increasing pressure to ensure supply chain sustainability and resilience. Environmentally sustainable supply chains and manufacturing involve reducing greenhouse gases, improving air quality and water management, and more renewable energy usage. Social sustainability ensures that patients...
-
Sector Analysis
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Thematic Analysis
Clinical Trials Sector Scorecard, Q2 2022 Update – Thematic Research
In Q2 2022, there was increased activity in the virtual care space. Compared to Q1 2022, Novo Nordisk initiated more trials with virtual components and posted more jobs related to virtual care. Daiichi Sankyo and Takeda are planning a study in Japan that will look at the feasibility of using a wearable device to track lifestyle habits. Sanofi announced several social initiatives, including the successful pricing of its first bond linked to improving access to essential medicine, the launch of...
-
Thematic Analysis
Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update – Thematic Research
The genomics landscape was active in Q2 2022, with scores increasing for several companies. This includes Merck & Co, whose score increased to 4 due to an increase in forecasted sales for several Phase II candidates, including its oncolytic vaccine Cavatak (gebasaxturev), an mRNA vaccine, and its recombinant vector vaccine V-184 for Chikungunya fever. In Regenerative Medicine, AstraZeneca saw an increase in its score due to forecasted global sales for its oligonucleotide AZD-8601 and an increase in posted jobs in...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...